Q2 delivered robust 19% revenue growth, strong global adoption of da Vinci and Ion platforms, and a 16% rise in total procedures. Guidance for 2026 remains positive, with continued innovation, stable capital demand, and strategic cost-lowering initiatives supporting future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.